Chemical formula: C₃₀H₅₃N₃O₆ Molecular mass: 551.758 g/mol PubChem compound: 5493444
Aliskiren is an orally active, non-peptide, potent and selective direct inhibitor of human renin. By inhibiting the enzyme renin, aliskiren inhibits the RAAS at the point of activation, blocking the conversion of angiotensinogen to angiotensin I and decreasing levels of angiotensin I and angiotensin II.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
ATC code | Group title | Classification |
---|---|---|
C09XA02 | Aliskiren | C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09X Other agents acting on the renin-angiotensin system → C09XA Renin-inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Title | Information Source | Document Type | |
---|---|---|---|
RASILEZ Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
TEKTURNA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Aliskiren is an active ingredient of these brands:
United States (US)
Austria (AT)
Canada (CA)
Croatia (HR)
Cyprus (CY)
Estonia (EE)
France (FR)
Hong Kong (HK)
Italy (IT)
Japan (JP)
Lithuania (LT)
Mexico (MX)
Netherlands (NL)
Poland (PL)
Romania (RO)
South Africa (ZA)
Spain (ES)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.